Learn a different way to fight HIV with FUZEON

  • FUZEON targets HIV outside the cell and blocks it before it enters and infects the cell
  • FUZEON is always used in combination with other HIV meds
    • New agents, such as raltegravir and maraviroc, may have an enhanced effect when used in a regimen that includes FUZEON1-3
  • FUZEON is active against HIV that is resistant to other HIV meds
  • FUZEON has a unique mechanism of action and attacks HIV in a new way

You could reach undetectable–even if you haven´t been there in a long time.

In just 90 days, patients in the TORO trials whose regimens included FUZEON showed these results compared to regimens without FUZEON:

Rapid decreases in viral load

Median time to ≥1 log10 viral load decrease from baseline in the TORO trials (FUZEON-based regimens: n=661, regimens without FUZEON: n=334)4

 

Graph showing rapid decreases in viral load from the TORO trails.

1 in 3 patients reached undetectable* by 90 days

After just 12 weeks of treatment, twice as many patients reached undetectable* taking a FUZEON-based regimen as those taking a regimen without FUZEON.5

Undetectable* at 90 days5

 

Graph showing percent of patients with FUZEON vs without FUZEON who were undetectable at 90 days

Increased CD4 count at 90 days6

 

Increased CD4 count at 90 days


*<400 copies/mL

Undetectable† at 48 weeks1,2

The following chart shows results from BENCHMRK, an ongoing multicenter, double-blind, randomized study to evaluate the safety and efficacy of raltegravir plus optimized background therapy (OBT) versus placebo plus OBT in patients failing antiretroviral therapy (ART) with HIV resistant to 3 classes of oral ART.1,2

In BENCHMRK studies, here are the percentage of patients with HIV-RNA <50 copies/mL at week 48 by selected ARVs in OBT1,2

 

Percentage of Patients with HIV-RVA


Only FUZEON-naÏve and darunavir-naÏve patients were included in this analysis. Baseline characteristics of both patients who used and did not use FUZEON were not presented.

†<50 copies/mL

A lower incidence of most common adverse events7‡

People taking FUZEON in combination with other antiretroviral drugs experienced fewer of the most common ARV adverse events compared with patients on regimens without FUZEON.

 

Adverse events rates per 100 patient-years of exposure

‡ Excluding injection site reactions.

1. Cooper D, Gatell J, Rockstroh J, et al. 48-Week Results from BENCHMRK-1, a Phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections. February 3-6, 2008; Boston, MA. Poster 788.

2. Steigbigel R, Kumar P, Eron J, et al. 48-Week Results from BENCHMRK-2, a Phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections. February 3-6, 2008; Boston, MA. Poster 789.

3. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2007; Chicago, IL. Presentation H-718a.

4. Bartlett JA, Salgo M, DeMasi R. Early viral load responses on enfuvirtide in heavily treatment-experienced patients. 15th International AIDS Conference. July 11-16, 2004; Bangkok, Thailand. Poster TuPeB4484.

5. Data on file (Ref. 118-011), Genentech USA, Inc., South San Francisco, CA 94080.

6. Data on file (Ref. 118-012), Genentech USA, Inc., South San Francisco, CA 94080.

7. Reynes J, Arastéh K, Clotet B, et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS. 2007;21(8):533-543.

Adobe Flash Player is required to view this content.Please download Adobe Flash Player.